Drug Trial Radar · NCT03482232
Consequences of Doing What Should Not be Done in Primary Care
Last checked: Nov 19, 2026Latest source record: Apr 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
750,000
Actual
Start
Oct 14, 2018
Primary completion
Dec 5, 2019
Study completion Feb 10, 2020
Sponsor
- Lead sponsor
- Universidad Miguel Hernandez de ElcheAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Osasunbidea; Servicio Madrileño de Salud, Madrid, Spain; Fondo de Investigacion Sanitaria; AQuAS; Agencia de Calidad Sanitaria de Andalucía; Ministerio de Sanidad, Servicios Sociales e Igualdad; Servicio Aragones De Salud; Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana; Generalitat Valenciana; MurciaSalud; Osakidetza; Castilla-La Mancha Health Service
- First posted
- Mar 29, 2018
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Retrospective observational study in a random selection of 5% of digital records active between 2014 and 2017 to quantify the frequency of Do not do primary care recommendations, calculating the over-cost related to them and study reviewing a random selection of cases previously identified to determine whether patient suffered adverse events and their over-cost.
Conditions
- Overdose
- Adverse Event
Interventions
BenzodiazepinesDrug
Benzodiazepines for insomnia, agitation or delirium in people older than 65
Non-steroidal anti-inflammatory drugsDrug
Non-steroidal anti-inflammatory drugs in patients with cardiovascular disease, chronic kidney disease, hypertension, heart failure or liver cirrhosis
paracetamolDrug
paracetamol 1g for more than 3 days
Antimicrobial agentDrug
antibiotic in acute bronchitis when the patient does not suffer from COPD, heart failure, diabetes or kidney disease or is undergoing active chemotherapy
Lipid-lowering drugDrug
Lipid-lowering drugs in patients older than 75 years without previous cardiovascular events
Prostate cancerDiagnostic test
Screening for prostate cancer in asymptomatic patients
LumbagoRadiation
image tests in non-specific lumbago
Antimicrobial agentDrug
antibiotics for pharyngitis (infants)
MucolyticDrug
mucolytics, antitussives or antibiotics for upper respiratory infections (infants)
Ibuprofen and paracetamolDrug
treatment with ibuprofen and paracetamol (infants)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Medical overuseTime frame: Three years
- Medical overuseTime frame: Three years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
FISABIO
Elche, Alicante, Spain
Universidad Miguel Hernández
Elche, Alicante, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.